Sulbactam sodium is a parenterally-active, β-lactamase inhibitor recently
introduced as a 1: 1 combination product with cefoperazone. Like clavulanic acid,
the first agent of this type to b e introduced, sulbactam enhances the effectiveness
of β-lactam antibiotics against resistant strains.
A semi-synthetic β-lactamase inhibitor. It is used in combination with β-lactam antibiotics as antibacterial.
ChEBI: Sulbactam sodium is an organooxygen compound and an organonitrogen compound. It is functionally related to an alpha-amino acid.
Sulbactam sodium is semi-synthetic antibiotic of penicillinic group. Start
material for it's synthesis is 6-aminopenicillanic acid. First 6-aminopenicillanic
acid was isolated in 1957 year from benzylpenicilline as resalt of treating of it
by penicillinaze. Benzylpenicilline is produced by microorganism of genus
Streptomyces.
Further, 6-aminopenicillanic acid reacted with bromine, hydrochloric acid and
NaNO2. As a result the 6,6-dibromopenicillanic acid was obtained.
6,6-Dibromopenicillanic acid was oxidized by KMnO4, to give 6,6-dibromo-1,1-The 6,6-dibromo-1,1-dioxopenicillanic acid in presence of Fe was converted to
the 1,1-dioxopenicillanic acid (sulbactam acid). The sulbactam acid was
treated by sodium 2-ethylhexanoate and crude sulbactam sodium was
obtained.
Sulbactam was synthesized by Pfizer Research Laboratories in 1977 in the course of screening for β-lactamase inhibitors. It shows strong activity against penicillinase and moderate activity against cephalosporinase. Sulbactam itself shows activity against some gramnegative bacteria but no activity against most pathogenic bacteria. The use of sulbactam in combination with cefoperazone, which is partially hydrolyzed by penicillinase, is under study along with its use as an esterified complex with ampicillin (sultamicillin) for therapy of cefoperazone-ampicillin-resistant infections.
Poison by intravenous route. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx and SOx
